Ronald Vender

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai et al. · Journal of the American Academy of Dermatology · 2016 · 304 citations

Medicine, Dermatology, Immunology +14

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Kenneth B. Gordon, Peter Foley, James G. Krueger et al. · The Lancet · 2021 · 284 citations

Medicine, Dermatology, Pharmacology +6

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Andrew Blauvelt, Kim Papp, Alice B. Gottlieb et al. · British Journal of Dermatology · 2019 · 172 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

Andrew Blauvelt, C. Leonardi, Boni E. Elewski et al. · British Journal of Dermatology · 2020 · 117 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Tiago Torres, L. Puig, Ronald Vender et al. · American Journal of Clinical Dermatology · 2021 · 116 citations · Full text

Medicine, Dermatology, Immunology +16